8-K current report · filed Oct 6, 2026

ArriVent BioPharma, Inc. (AVBP) 8-K Current Report: October 6, 2026

Item 7.01Item 8.01Item EX-99.1AVBP overview

Short answer

ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Phase 3 FURVENT trial update for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC.

ArriVent BioPharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Phase 3 FURVENT trial update for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC
  • Clinical update potentially material to firmonertinib’s development path and ArriVent’s valuation
  • Press release dated October 6, 2026, contains the substantive trial details

Item 8.01 · Other Events

  • Item 8.01 incorporates the Item 7.01 press release, excluding its second paragraph
  • Investor significance depends on the underlying press release disclosure, not this incorporation reference

Item EX-99.1 · Exhibit EX-99.1

  • FURVENT failed its primary BICR PFS endpoint, materially weakening firmonertinib’s first-line EGFR exon 20 insertion NSCLC approval case
  • BICR median PFS: 11.0 months at 240mg vs 9.5 months control, p=0.0654, HR 0.75
  • Confirmed BICR response rate: 60% at 240mg vs 33% control, but secondary benefits may not offset the failed primary endpoint
  • Investigator-assessed PFS favored 240mg: 11.1 months vs 7.1 months control, HR 0.61
  • Safety remained comparable, with Grade ≥3 treatment-related events at 26% for 240mg vs 40% control

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ArriVent BioPharma, Inc. 8-K filings

Get the next AVBP 8-K as it lands

Follow AVBP for push alerts, or ask the research agent what this filing means.